Blog
About

0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Treatment with AMG 420, an Anti-B-Cell Maturation Antigen (BCMA) Bispecific T-Cell Engager (BiTE®) Antibody Construct, Induces Minimal Residual Disease (MRD) Negative Complete Responses in Relapsed and/or Refractory (R/R) Multiple Myeloma (MM) Patients: Results of a First-in-Human (FIH) Phase I Dose Escalation Study

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: BCMA, a member of the TNF receptor family, is expressed on MM and plasma cells. AMG 420, formerly BI 836909, binds BCMA on tumor cells and plasma cells and CD3 on T cells, resulting in T-cell mediated lysis of BCMA+ cells. Objectives of this study of AMG 420 in patients with R/R MM included assessing safety and tolerability and anti-tumor activity per IMWG 2006.

          Methods: This is a FIH phase I dose escalation study (NCT02514239) of 6-week cycles of AMG 420 (1 cycle=4 weeks continuous IV infusion, 2 weeks off). Single-patient cohorts [0.2-1.6 µg/day (d)] were followed by cohorts of 3-6 patients (3.2-800 µg/d). Eligible patients had R/R MM and progression after ≥2 prior treatment lines (including proteasome inhibitor and immunomodulators); excluded were patients with plasma cell leukemia, extramedullary relapse, known central nervous system involvement, or prior allogeneic stem cell transplant. Treatment continued for up to 5 cycles or until disease progression (PD), start of new therapy, toxicity, withdrawal of consent, or investigator decision; 5 more cycles could be given per investigator for perceived benefit. MRD response was defined for this study as <1 tumor cell / 104 normal cells in the bone marrow per FACS using antibodies to cytIgλ, cytIgκ, CD19, CD56 or CD138, CD38, and CD45.

          Results: As of May 22, 2018, 35 patients received AMG 420 (0.2-800 µg/d). Patients discontinued for PD (n=21), adverse events [AE, n=7, including 2 dose-limiting toxicities (DLTs)], or completed 10 cycles (n=2); 5 remain on study. Mean (SD) age was 63.8 (8.7) years, median 65 years, min-max 39-79 years, and 22 (63%) were male. Median MM disease duration was 5.4 (Q1: 3.3, Q3: 7.4) years, min-max 1.3-20 years, and median # of prior therapies was 4 (Q1: 2, Q3: 5), min-max 2-13. Patients (n=35) were treated for a mean (SD) of 2.3 (2.3) cycles and a median (min-max) of 1 (1-10) cycles; responders (n=8) were treated for a mean (SD) of 5.3 (3.3) cycles and a median (min-max) of 3.5 (2-10) cycles, including those with treatment ongoing.

          Regarding safety, one patient in the 50 µg/d cohort died after the first cycle from acute respiratory distress due to concurrent flu and aspergillosis not considered related to treatment. Of those with serious AEs (n=17, 49%), 12 required hospitalization and another 3 had prolonged hospitalization. Serious AEs included infections (n=10, 29%, 3 device-related, 3 pneumonias, 2 catheter site, 1 aspergillus, 1 influenza, and 1 fever/infection), cytokine release syndrome (CRS, n=3), and 1 each of peripheral polyneuropathy (PPN), cardiac failure, edema, pyrexia, biliary obstruction, and renal failure. Treatment-related serious AEs included CRS (n=3, 2 grade 1 and 1 grade 3) and 1 each of PPN (grade 3), edema (grade 3), and pyrexia (grade 1). No anti-AMG 420 antibodies were detected up to 800 μg/d and no DLTs were observed up to 400 µg/d. In this study, 800 µg/d was determined to not be tolerable as 2/3 patients experienced DLTs: 1) Grade 3 CRS within 1d of initiating treatment with fever, hypertension, tachycardia, and retrograde amnesia; symptoms resolved after stopping drug, and 2) Grade 3 PPN that required hospitalization with subsequent complete recovery; after 15d of treatment, M protein decreased by 60%.

          Six patients had complete responses (CRs), 1 each at 6.5, 100, and 200 µg/d, and 3 at 400 µg/d; responses are ongoing for these last 3 (≥4.6 months). There also were two partial remissions, a partial response (PR) at 50 µg/d and a very good partial response at 800 µg/d. Response duration was for up to 8 cycles (1 patient had PR cycles 3-10). All patients at 400 µg/d (3/3) had MRD negative CRs. In the dose confirmation cohort enrolled after May 22, 2 of 3 patients had PRs as of cycle 1. Thus, at the dose of 400 µg/d, the objective response rate is 5/6 (83%); all 5 are still responding on treatment. Pharmacokinetic analyses show that responders had higher free-drug exposure levels than non-responders [median (range) of 3,225 (36-108,000) vs 97 (27-1,380) pg/mL].

          Conclusions: In this FIH study, AMG 420, a short half-life BiTE® targeting BCMA, showed encouraging evidence of activity in patients with R/R multiple myeloma. During dose escalation, all 3 patients dosed with 400 µg/d had MRD-negative CRs, with 2 more responders in the dose confirmation cohort to date; 3 patients at lower doses also attained CRs. No major toxicities were observed up to 400 µg/d, which is a recommended dose for further investigation; DLTs at 800 µg/d were CRS and PPN.

          Figure Figure.

          Disclosures

          Topp: Regeneron Pharmaceuticals, Inc.: Honoraria, Research Funding; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Research Funding; F. Hoffmann-La Roche Ltd: Membership on an entity's Board of Directors or advisory committees, Research Funding; Boehringer Ingelheim: Research Funding. Zugmaier:Amgen Inc.: Consultancy, Employment, Patents & Royalties: 20170327581, 9688760, 20170122947, 9486475, 20160208001, 9192665, 20150071928, 8840888, 20140227272, 20140228316, 20130323247, 20130287774, 20130287778, 20110262440, 20100112603, 7700299, 20070037228. Moreau:Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees. Facon:Takeda: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Membership on an entity's Board of Directors or advisory committees; Karyopharm: Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Oncopeptides: Membership on an entity's Board of Directors or advisory committees. Munzert:Boehringer Ingelheim: Employment, Patents & Royalties: and other intellectual property .

          Related collections

          Author and article information

          Journal
          Blood
          American Society of Hematology
          0006-4971
          1528-0020
          November 29 2018
          November 29 2018
          : 132
          : Supplement 1
          : 1010
          Affiliations
          [1 ]University Hospital of Würzburg, Würzburg, Germany
          [2 ]Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
          [3 ]Amgen Research (Munich), GmbH, Munich, Germany
          [4 ]University of Toulouse, Toulouse, France
          [5 ]University Hospital Hôtel-Dieu, Nantes, France
          [6 ]Kempten Clinic, Kempten, Germany
          [7 ]Ulm University, Ulm, Germany
          [8 ]Regional University Hospital of Lille, Lille, France
          [9 ]Boehringer Ingelheim, Ingelheim am Rhein, Germany
          Article
          10.1182/blood-2018-99-109769
          © 2018

          Comments

          Comment on this article